Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.000
+0.010 (0.50%)
At close: Mar 13, 2026, 4:00 PM EDT
1.921
-0.079 (-3.95%)
After-hours: Mar 13, 2026, 5:40 PM EDT

Inhibikase Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
--0.260.123.10.7
Revenue Growth (YoY)
--111.03%-96.02%343.92%-37.79%
Gross Profit
--0.260.123.10.7
Selling, General & Admin
22.5211.386.736.226.512.62
Research & Development
30.6317.2113.6212.0311.360.89
Other Operating Expenses
2.02-----
Total Operating Expenses
55.1628.5920.3518.2517.873.52
Operating Income
-51.13-28.59-20.09-18.13-14.77-2.82
Interest Income
3.471.071.060.07-0.02-
Interest Expense
------0.03
Total Non-Operating Income (Expense)
3.471.071.060.07-0.02-0.03
Pretax Income
-47.66-27.52-19.03-18.05-14.79-2.85
Net Income
-47.66-27.52-19.03-18.05-14.79-2.85
Net Income to Common
-47.66-27.52-19.03-18.05-14.79-2.85
Shares Outstanding (Basic)
85246431
Shares Outstanding (Diluted)
85246431
Shares Change (YoY)
1080.69%293.35%42.74%39.15%121.72%0.39%
EPS (Basic)
0.48-1.16-3.16-4.28-4.86-2.10
EPS (Diluted)
0.48-1.16-3.16-4.28-4.86-2.10
Free Cash Flow
-25.64-19.15-18.1-17.59-14.3-1.13
Free Cash Flow Per Share
-0.30-0.81-3.00-4.17-4.71-0.83
Gross Margin
--100.00%100.00%100.00%100.00%
Operating Margin
---7711.98%-14686.17%-476.23%-403.52%
Profit Margin
---7304.73%-14625.85%-476.88%-407.73%
FCF Margin
---6947.87%-14253.37%-461.11%-161.69%
EBITDA
-51.06-28.56-19.91-18.12-14.77-2.82
EBITDA Margin
---7643.88%-14680.72%-476.23%-403.52%
EBIT
-51.13-28.59-20.09-18.13-14.77-2.82
EBIT Margin
---7711.98%-14686.17%-476.23%-403.52%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q